DGIdb - GOSERELIN Drug Record

GOSERELIN chembl:CHEMBL1201247 ApprovedAntineoplastic

Alternate Names:

ICI-118630
ZOLADEX
GOSERELIN
GOSERELIN ACETATE
ZOLADEX®
ICI 118630
DECAPEPTIDE I
ZD9393
rxcui:50610
chembl:CHEMBL1201247
chemidplus:65807-02-5
drugbank:00014
pubchem.compound:5311128

Drug Info:

FDA Approval	1989
Drug Class	peptide
Drug Indications	Antineoplastic Agents, Hormonal
Year of Approval	1989
Drug Class	antineoplastic agents, hormonal

(3 More Sources)

Publications:

Kirby et al., 2009, Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer., BJU Int.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Kvorning et al., 2007, Suppression of testosterone does not blunt mRNA expression of myoD, myogenin, IGF, myostatin or androgen receptor post strength training in humans., J. Physiol. (Lond.)

GOSERELIN LHCGR

Interaction Score: 4.29

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
20053189 17016423 17139284

Sources:
TdgClinicalTrial TEND
GOSERELIN MYOD1

Interaction Score: 2.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17095559

Sources:
NCI
GOSERELIN GNRH1

Interaction Score: 0.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
GOSERELIN PGR

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
GOSERELIN ESR2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GOSERELIN ESR1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA

TEND: GOSERELIN
- Version: 01-August-2011
Alternate Names:

GOSERELIN Primary Drug Name

Drug Info:

Drug Class antineoplastic agents, hormonal

Year of Approval 1989

Publications:
TdgClinicalTrial: GOSERELIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic Agents, Hormonal

Drug Class peptide

FDA Approval 1989

Publications:
NCI: GOSERELIN
- Version: 14-September-2017
Alternate Names:

C1374 NCI drug code

Drug Info:

Publications:

Kvorning et al., 2007, Suppression of testosterone does not blunt mRNA expression of myoD, myogenin, IGF, myostatin or androgen receptor post strength training in humans., J. Physiol. (Lond.)
TTD: Goserelin
- Version: 2020.06.01
Alternate Names:

D00BCG TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201247
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
PharmGKB: goserelin
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
FDA: Goserelin
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

GOSERELIN Drug Record

GOSERELIN chembl:CHEMBL1201247 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

GOSERELIN LHCGR

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 20053189 17016423 17139284

Sources: TdgClinicalTrial TEND

GOSERELIN MYOD1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17095559

Sources: NCI

GOSERELIN GNRH1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

GOSERELIN PGR

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

GOSERELIN ESR2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

GOSERELIN ESR1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

TEND: GOSERELIN

Alternate Names: GOSERELIN Primary Drug Name

Drug Info: Drug Class antineoplastic agents, hormonal Year of Approval 1989

Publications:

TdgClinicalTrial: GOSERELIN

Alternate Names:

Drug Info: Drug Indications Antineoplastic Agents, Hormonal Drug Class peptide FDA Approval 1989

Publications:

NCI: GOSERELIN

Alternate Names: C1374 NCI drug code

Drug Info:

Publications: Kvorning et al., 2007, Suppression of testosterone does not blunt mRNA expression of myoD, myogenin, IGF, myostatin or androgen receptor post strength training in humans., J. Physiol. (Lond.)

TTD: Goserelin

Alternate Names: D00BCG TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201247

Alternate Names:

Drug Info:

Publications:

PharmGKB: goserelin

Alternate Names:

Drug Info:

Publications:

FDA: Goserelin

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
20053189 17016423 17139284

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
17095559

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Alternate Names:

GOSERELIN Primary Drug Name

Drug Info:

Drug Class antineoplastic agents, hormonal

Year of Approval 1989

Drug Info:

Drug Indications Antineoplastic Agents, Hormonal

Drug Class peptide

FDA Approval 1989

Alternate Names:

C1374 NCI drug code

Publications:

Kvorning et al., 2007, Suppression of testosterone does not blunt mRNA expression of myoD, myogenin, IGF, myostatin or androgen receptor post strength training in humans., J. Physiol. (Lond.)

Alternate Names:

D00BCG TTD Drug ID